Effective Intravenous Therapy for Neurodegenerative Disease With a Therapeutic Enzyme and a Peptide That Mediates Delivery to the Brain

• Published in: Molecular therapy Vol. 22; no. 3; pp. 547 - 553
• Main Authors: Meng, Yu, Sohar, Istvan, Sleat, David E, Richardson, Jason R, Reuhl, Kenneth R, Jenkins, Robert B, Sarkar, Gobinda, Lobel, Peter
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2014; Elsevier Limited; Nature Publishing Group
• Subjects: Administration, Intravenous; Aminopeptidases - metabolism; Animals; Apolipoproteins; Apolipoproteins E - metabolism; Blood-Brain Barrier - metabolism; CHO Cells; Cricetulus; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - metabolism; Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug dosages; Enzyme Replacement Therapy; Enzymes; Humans; Intravenous therapy; Low density lipoprotein receptors; Lysosomes - metabolism; Mice; Neuronal Ceroid-Lipofuscinoses - drug therapy; Neuronal Ceroid-Lipofuscinoses - pathology; Neuronal Ceroid-Lipofuscinoses - physiopathology; Original; Peptides; Peptides - administration & dosage; Proteins; Recombinant Proteins; Serine Proteases - metabolism; Toxicity; United States > US; Minnesota; New Jersey
• DOI: 10.1038/mt.2013.267
• ISSN: 1525-0016

The blood–brain barrier (BBB) presents a major challenge to effective treatment of neurological disorders, including lysosomal storage diseases (LSDs), which frequently present with life-shortening and untreatable neurodegeneration. There is considerable interest in methods for intravenous delivery of lysosomal proteins across the BBB but for the most part, levels achievable in the brain of mouse models are modest and increased lifespan remains to be demonstrated. In this study, we have investigated delivery across the BBB using a mouse model of late-infantile neuronal ceroid lipofuscinosis (LINCL), a neurodegenerative LSD caused by loss of tripeptidyl peptidase I (TPP1). We have achieved supraphysiological levels of TPP1 throughout the brain of LINCL mice by intravenous (IV) coadministration of recombinant TPP1 with a 36-residue peptide that contains polylysine and a low-density lipoprotein receptor binding sequence from apolipoprotein E. Importantly, IV administration of TPP1 with the peptide significantly reduces brain lysosomal storage, increases lifespan and improves neurological function. This simple “mix and inject” method is immediately applicable towards evaluation of enzyme replacement therapy to the brain in preclinical models and further exploration of its clinical potential is warranted.